Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase 1 / 2 Trial of Belantamab Mafodotin, Lenalidomide, and Daratumumab in Relapsed or Newly Diagnosed Multiple Myeloma Patients

NCT04892264 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT04892264
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04892264 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase 1 / 2 Trial of Belantamab Mafodotin, Lenalidomide, and Daratumumab in Relapsed or Newly Diagnosed Multiple Myeloma Patients
Lead sponsor
Mayo Clinic
Phase
Phase 1
Overall status
Terminated
Start date
June 3, 2021
Completion date
March 18, 2024
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

plasma cell myeloma, recurrent plasma cell myeloma, refractory plasma cell myeloma